containing protein 4 (BRD4) has been demonstrated to play critical roles in cellular proliferation and cell cycle progression. In this study, using the BRD4 inhibitor Fragment 9 as a lead compound, a series of imidazolopyridone derivatives were designed and tested for their inhibitory activity against BRD4 protein in vitro. Among them, HB100-A7 showed excellent BRD4(1) inhibitory activities with an IC50
已证明含
溴结构域蛋白 4 (BR
D4) 在细胞增殖和细胞周期进程中发挥关键作用。本研究以BR
D4抑制剂片段9为先导化合物,设计并测试了一系列
咪唑并
吡啶酮衍
生物对BR
D4蛋白的体外抑制活性。其中,HB100-A7显示出优异的 BR
D4(1) 抑制活性,IC 50值为 0.035 μM,在放大发光邻近均相测定 (Alphascreen) 中。M
TT实验结果表明HB100-A7能抑制胰腺癌细胞的增殖。此外,流式细胞术进一步说明HB100-A7治疗导致 G0/G1 期停滞并促进 BxPc3 细胞的凋亡。此外,体内研究发现HB100-A7在胰腺小鼠肿瘤模型 (Panc-02) 中显示出显着的肿瘤生长抑制作用。此外,IHC 染色表明HB100-A7诱导胰腺癌肿瘤组织中的细胞凋亡。总之,这项研究首次表明,HB100-A7是一种很有前景的先导化合物,可进一步开发为靶向 BR
D4 蛋白的新一代小分子
抑制剂。